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In addition to flow cytometry we want to show how modern
microscopes help to perform a variety of routine and specialty
applications.
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Cancer cells display altered methylation signatures distin-
guishing them from normal cells. Originating from all tissues
and cells of the body cell-free DNA (cfDNA) including aberrantly
methylated DNA reflect epigenetic aberrations occurs not only
in tumor cells but also in tumor microenvironment. Actually,
aberrantly methylated cfDNA has proved to be a promising
biomarker for noninvasive detection of cancer with several
clinically-certified tests (Epi-pro Colon, Epi-pro Lung, Colo-
guard). However only one test (Epi-pro Colon) uses blood
plasma – the most convenient source of cfDNA. Input of tissue
and age specific methylation along with unidentified reasons lead
to the presence of molecules with every conceivable cytosine-
methylation patterns which decrease probability of tumor DNA
identification. Among numerous variants of cfDNA methylation
patterns only few reflect cancer related changes. To identify those
tumor-specific profiles single nucleotide resolution of methylated
cytosine locations in the individual circulating DNA molecules is
obviously required.
We performed target bisulfite sequencing of potential prostate
cancer (PC) cfDNA markers (GSTP1; RNF219) isolated from blood
plasma of 18 healthy donors (HD), 17 benign hyperplasia (BPH)
and 20 PC patients using MiSeq platform (Illumina). RNF219 gene
was shown to have high diagnostic potential in our previous
comparative study of cfDNA from HD, PC and BHP patients using
HCGI12k microarrays (Cortese, et al., 2012). GSTP1 is a common
pathological DNA methylation event in PC and is most widely
studied and promising methylation marker in the cfDNA of PC
patients (Wu, et al., 2011).
Selected loci were amplified after bisulfite conversion (Zymo
Research) of cfDNA with methyl-independent barcoded primers
and sequenced with coverage ranging from 23509 to 143953.
Identification of CpG methylation status in DNA fragments was
performedwith the BiQ Analyzer HT Software. All statistical anal-
ysis was performed using R Statistical Software (version 3.1.1) To
reveal diagnostically significant differences, several approaches
to data analysis were used. Conventional approach is a prediction
of patient’s diagnosis based on differences in methylation level
of CpG-sites. Another approach used in this study relies on
discrimination of cancer-related correlation between methylation
statuses of CpG-sites within individual molecules of cfDNA –
Intramolecular Correlation of Methylation Statuses (ICoMS).
Study population was randomly subsampled into training and
test cohorts. The logit regression model based on methylation
level of CpG-sites achieved an area under the ROC curve (AUC)
exceeding 0.94 in both cohorts for GSTP1 gene and 0.81 – for
RNF219 gene. A novel approach to identify diagnostic significance
of cfDNA methylation was based on comparison of correlation
matrices (pairwise phi coefficient between methylation statuses
of CpG sites) for HD, BHP and PC groups. Binomial regression
models with LASSO penalization were used to predict patient’s
diagnosis. ROC curves for fitted models show AUC, specificity
and sensitivity as 0.99, 100% and 92% for GSTP1 gene and 0.99,
100% and 90% for RNF219 (test cohort).
The ICoMS approach estimates diagnostic value of target
genes and reveals cancer-related cytosine methylation. That
could potentially input in gene expression, identify the features
of tumor physiology and on a par with conventional approaches
provide helpful information for rational design of noninvasive,
methylation-specific cfDNA-based diagnostics for PC.
Moreover, the planned further evaluation of relationship
between the revealed correlations associated with cancer
and tumor biology could increase the basic knowledge of
carcinogenesis.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.012
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Background: Breast cancer ranks the first among female onco-
logical diseases and ranks the second after lung cancer among
causes of cancer related deaths. Use of contemporary anticancer
drugs significantly enhanced possibilities of cancer therapy.
However, most of medicines against cancer have such disadvan-
tages as toxicity, narrowness of therapeutic action, and
emergence of drug resistance. Recently, an approach based on
potential of dendritic cells (DCs) to induce formation of cytotoxic
T-cell immune response against cancer cells is widely used. Prim-
ing of dendritic cells by DNA-constructs encoding immunogenic
epitopes of tumor antigens is regarded as a rather promising
approach to design cancer vaccines. The aim of this study is to
construct, obtain and study expression in eukaryotic cells of
recombinant plasmid – candidate DNA-vaccines inducing T-cell
immune response against breast cancer.
Materials and methods: Using the PolyCTLDesigner software,
DNA-vaccine construct was made encoding polyepitope T-cell
immunogen BC-A*0201. Gene encoding target immunogen was
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synthesized and cloned in the composition of plasmid pcDNA3.1
that is eukaryotic expression vector. Accuracy of gene insertion
encoding polyepitopeimmunogen was verified using restriction
analysis. Obtained target plasmid pBC-A*0201 – candidate DNA-
vaccine was used for evaluation of gene expression in transfected
eukaryotic cells 293T and dendritic cells by means of flow cytoflu-
orometry and immunohistochemistry using MAT to p24 epitope-
marker inserted into the structure of target plasmid. Dendritic
cells were obtained from peripheral blood precursors by 2-h plas-
tic adhesion. The nonadherent cells were removed 2 h later and
the adherent monolayer was cultivated in the medium containing
growth factors (GM-CSF and IL-4) according to (Naik, 2010; Ganul
and Khranovskaya, 2012). Transfection of immature DCs (iDC)
was performed by using the reagents purchased from Promokine.
Further cultivation of iDCs was carried out in the medium con-
taining TNF- a to obtain fully mature DCs (mDC). Analysis of
mDCsurface markers expression was made using MAO (HLA-
DR, CD83, CD86) and flow cytofluorometer (BD FACSCalibur).
Results: Plasmid pBC-A*0201 encoding epitopes of breast can-
cer antigens was constructed and produced in preparative
amount. Using the method of intracellular staining of product
of expression by specific MAO 29F2 to epitope p24, we showed
expression of gene BC-A*0201 in eukaryotic cells 293T and
dendritic cells transfected by plasmid pBC-A*0201. Maturity of
dendritic cells was also proved.
Conclusion: Thus, obtained candidate DNA-vaccine encoding
target polyepitopeimmunogen provides synthesis of relevant
protein in the eukaryotic cells culture. In future, we plan to study
biological activity of DNA-vaccine to evaluate level of induction of
cytotoxic response against SKBR3 breast cancer cells.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.013
P67
Use of extracellular RNA from urine for the diagnosis of prostate
cancer
O. Bryzgunovaa, E. Lekhnova,*, T. Skvortsovaa, E. Morozkina,c,
I. Zaporozhchenkoa, A. Grigorievaa, M. Zaripovb, E. Ryabchikovaa,
V. Vlassova, P. Laktionova,c. aNovosibirsk Regional Oncology Center,
Russian Federation, b Institute of Chemical Biology and Fundamental
Medicine SD RAS, Novosibirsk, Russian Federation, cAcademician E.N.
Meshalkin Novosibirsk State Research Institute of Circulation Pathology,
Russian Federation
⇑
Corresponding author.
Differently sized microparticles, including exosomes (30–
100 nm), prostasomes (50–500 nm), oncosomes (50–500 nm) and
other microparticles (100–1000 nm) were found in blood and
urine. Exosomes from prostate cancer (PCa) patients can poten-
tially contain cancer-specific nucleic acids, and thus can repre-
sent a valuable source of diagnostic material. In this study, we
have investigated microvesicles and miRNA from urine of healthy
donors and PCa patients. To isolate miRNAs from urine and
microparticles, novel methods for miRNA isolation were elabo-
rated (Rus. patent application No 2014137763, priority date
17.09.2014). The study population included 14 patients with PCa
(63–82 years, T2-3NxMx1) and control group of 20 healthy
volunteers with no previous history of prostate disease
(48–73 years). Urine was clarified by two serial centrifugations at
400g, 20 C, 20 min and at 17000g, 20 C, 20 min. Microparticles
were precipitated from the resulting supernatant by high-speed
centrifugation at 100000g, 18 C, 90 min, the pellet was resus-
pended and pelleted by centrifugation under the same condi-
tions. To isolate exosomes, total microparticles were filtered
through 0.1 lm pore filters and reprecipitated. The resulting pel-
lets were resuspended and exosome samples were investigated
by transmission electron microscopy (TEM). MiRNAs were iso-
lated by one-step single-phase protocol and purified using ‘‘BioSil-
ica” spin- columns (Zaporozhchenko et al., Anal. Biochem,
upcoming, doi: 10.1016/j.ab.2015.03.028) and by recently devel-
oped method based on precipitation of excess biopolymers,
allowing to isolate miRNAs with better efficiency than commer-
cially available kits. The size and quantity assessment of extracel-
lular RNAwere performed using capillary electrophoresis system
on Agilent 2100 Bioanalyzer. Concentrations of miRNAs (miR19b,
miR25, miR205, miR125b, miR126) were measured by qRT-PCR and
normalized to miR-16 using dCq method.
TEM demonstrated the presence of 20–300 nm microparticles
in urine of healthy donors and PCa patients. Approximately
50–70% of all urine microparticles are represented by 30–100 nm
exosomes and residual 30–50% by particles larger than 100 nm.
(The pool of urine microvesicles consists of 50–70% exosomes
and 30–50% particles larger than 100 nm.).
The major part of extracellular RNA found both in exosomes
and total microparticles fraction of healthy donors and patients
with PCa, is 25–200 nt long and can include tRNA (73–93 n.), 5.8
rRNA (150 n.), snoRNK (10–20 n.), snRNA (60–300 n.) piRNAs
(29–30 n.), miRNAs (20–25 n.), siRNA (21–25 n.). Concentration of
extracellular urine RNA in exosomes and total microparticles of
healthy donors and patients with PCa amounts to100 pg/ml of
urine on average.Receiver Operating Characteristic (ROC) curve
analysis of all miRNAs in samples isolated from total urine did
not demonstrate any diagnostic significance. In contrast, in train-
ing cohort concentration of miR-19b in exosomes and total
microparticles fraction provide 95%/75% and 93%/100% sensitivity
and specificity, respectively.
Thus, microparticles, isolated from urine of PCa patients
represent a valuable source of diagnostically significant miRNAs.
To investigate miR-19b, a large testing cohort is required. Search
for other potential miRNA-markers by microarray profiling of
cell-free miRNA isolated from urine of PCa patients is also
required to reveal a sold set of markers for confident PCa
diagnostics.
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